All In Biotech

Drug Trial Radar · NCT06315426

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR.

Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

240

Actual

Start

Mar 24, 2024

Primary completion

May 2025

Study completion Oct 2025

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Conditions

  • Allergic Rhinitis

Interventions

  • GR1802 injectionBiological

    Recombinant fully human anti-IL4Rα monoclonal antibody drug.

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in rTNSS( reflective total nasal symptom scores)Time frame: Over 2 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • Central Hospital of Qinghe County

    Xingtai, Hebei, China

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • The Central Hospital of Wuhan

    Wuhan, Hubei, China

  • Wuhan Union Hospital of China

    Wuhan, Hubei, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shandong Second Provincial General Hospital

    Jinan, Shandong, China

  • Liaocheng People's Hospital

    Liaocheng, Shandong, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, China

  • Yuncheng Central Hospital

    Yuncheng, Shanxi, China

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.